| Literature DB >> 20935522 |
Masanori Noguchi1, Takashi Mine, Nobukazu Komatsu, Shigetaka Suekane, Fukuko Moriya, Kei Matsuoka, Shigeru Yutani, Shigeki Shichijo, Akira Yamada, Uhi Toh, Kouichiro Kawano, Kouichi Azuma, Hirotsugu Uemura, Kiyotaka Okuno, Kazumasa Matsumoto, Hiroaki Yanagimoto, Ryuya Yamanaka, Masaaki Oka, Satoru Todo, Tetsuro Sasada, Kyogo Itoh.
Abstract
To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between overall survival and biomarkers, including cytotoxic T lymphocyte (CTL) and immunoglobulin G (IgG) responses to the vaccinated peptides, were investigated in 500 advanced cancer patients who received personalized peptide vaccination from October 2000 to October 2008. The best clinical response was assessed for in 436 patients, 43 patients (10%) had partial response, 144 patients (33%) had stable disease and 249 patients (57%) had progressive, with a median overall survival of 9.9 months. Both lymphocyte counts prior to the vaccination (P = 0.0095) and increased IgG response (P = 0.0116) to the vaccinated peptides, along with performance status (P < 0.0001), well correlated with overall survival. To confirm the superiority of IgG response to CTL response, the samples from advanced castration-resistant prostate cancer patients who survived more than 900 days (n=20) and those who died within 300 days (n=23) were analyzed further. As a result, both the numbers of peptides, to which increased IgG responses were observed, and the fold increases in IgG levels were significantly higher in long-term survivors (P = 0.000282 and P = 0.00045). In contrast, CTL responses were not statistically different between the two groups. Both lymphocyte numbers and IgG response were thus suggested to be biomarkers of cancer vaccine for advanced cancer patients.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20935522 DOI: 10.4161/cbt.10.12.13448
Source DB: PubMed Journal: Cancer Biol Ther ISSN: 1538-4047 Impact factor: 4.742